Preclinical studies indicate that inhibiting Gal-1 can slow atherosclerosis progression, reduce myocardial infarction-induced injury, and prevent adverse cardiac remodeling by modulating inflammation, endothelial dysfunction, and fibrosis [57,58]. This evidence concerns the gene LGALS1 and endothelial dysfunction.